Pharma Powerhouse: Novartis Stock Soars, But Is It a Safe Bet?

Novartis, a big name in the medicine world, has seen its stock price hit record highs. Over the past year, shares have jumped nearly 50%. This Swiss company makes a wide range of medicines, from cancer treatments to drugs for immune system disorders.

CEO's Optimistic Outlook

The company's CEO recently said that by mid-2026, Novartis will have very little risk from tariffs. This is good news because tariffs can make it more expensive to sell products in other countries. The CEO made these comments at a big meeting in Davos, Switzerland.

Financial Highlights

Looking at the numbers, Novartis is worth about $310.8 billion. Its stock price has gone up a lot recently. It hit a new high of $148.38 in January. The stock has also been doing well over the past month, up about 6.61%.

Expert Opinions

But what do the experts think? Analysts have given Novartis a "Moderate Buy" rating. They expect the company's earnings to grow in the next few years. However, some experts warn that stocks like Novartis can be risky. They can go up and down quickly, so investors need to be careful.